<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055547</url>
  </required_header>
  <id_info>
    <org_study_id>8521-002</org_study_id>
    <secondary_id>2013-000083-28</secondary_id>
    <nct_id>NCT02055547</nct_id>
  </id_info>
  <brief_title>A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)</brief_title>
  <official_title>A Single and Multiple-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8521 in Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
      MK-8521. The primary hypothesis is that MK-8521 is sufficiently safe and well-tolerated in
      healthy, lean and obese males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with an adverse event (AE) (Part 1)</measure>
    <time_frame>Up to Day 34</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinued treatment due to an AE (Part 1)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) 0-∞ for plasma concentration of participants treated with a single dose of MK-8521 (Part 1)</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of participants treated with a single dose of MK-8521 (Part 1)</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time taken to reach Cmax (Tmax) for plasma concentration of participants treated with a single dose of MK-8521 (Part 1)</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (T 1/2) for plasma concentration of participants treated with a single dose of MK-8521 (Part 1)</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an AE (Part 2)</measure>
    <time_frame>Up to Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinued treatment due to an AE (Part 2)</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-24hr for plasma concentration of participants treated with multiple doses of MK-8521 (Part 2)</measure>
    <time_frame>Up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for plasma concentration of participants treated with multiple doses of MK-8521(Part 2)</measure>
    <time_frame>Up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough plasma concentration (Ctrough) of participants treated with multiple doses of MK-8521(Part 2)</measure>
    <time_frame>Up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for plasma concentration of participants treated with multiple doses of MK-8521 (Part 2)</measure>
    <time_frame>Up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T 1/2 for plasma concentration of participants treated with multiple doses of MK-8521 (Part 2)</measure>
    <time_frame>Up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an AE (Part 3)</measure>
    <time_frame>Up to Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinued treatment due to an AE (Part 3)</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Slope of insulin secretion rate/glucose (ISR/G) during graded glucose infusion (GGI) due to treatment with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in time-weighted average (TWA) 0-24 hrs heart rate of participants treated with a single dose of MK-8521 (Part 1)</measure>
    <time_frame>Day 1 pre-dose and through Day 2 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TWA 0-24 hrs systolic blood pressure (BP) of participants treated with a single dose of MK-8521 (Part 1)</measure>
    <time_frame>Day 1 pre-dose and through Day 2 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TWA 0-24 hrs diastoliic BP of participants treated with a single dose of MK-8521 (Part 1)</measure>
    <time_frame>Day 1 pre-dose and through Day 2 after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TWA 0-24 hrs heart rate of participants treated with multiple doses of MK-8521 (Part 2)</measure>
    <time_frame>Day (-1) and up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TWA 0-24 hrs systolic BP of participants treated with multiple doses of MK-8521 (Part 2)</measure>
    <time_frame>Day (-1) and up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TWA 0-24 hrs diastolic BP of participants treated with multiple doses of MK-8521 (Part 2)</measure>
    <time_frame>Day (-1) and up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose (TWA 0-160 min) during GGI at Tmax due to treatment with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum glycemic excursion (Gmax) during GGI at Tmax due to treatment with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of ISR/G at the highest glucose infusion rate during GGI due to treatment with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-∞ for plasma concentration of participants treated with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for plasma concentration of participants treated with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for plasma concentration of participants treated with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T 1/2 for plasma concentration of participants treated with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of (ISR/G) during GGI at Tmax due to treatment with a single dose of MK-8521 (Part 3)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>19</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>100 - PBO (Part1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of 100 micrograms (mcg) subcutaneous (sc) MK-8521 in the first treatment period, and Placebo (PBO) in the second period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO - 300 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc PBO in the first treatment period, and 300 mcg MK-8521 in the second period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 - 300 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc 100 mcg MK-8521 in the first treatment period, and 300 mcg MK-8521 in the second period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 - PBO - 175 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, PBO in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 - 200 - 175 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, 200 mcg MK-8521 in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 - 200 - PBO (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, 200 mcg MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO - 200 - 175 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc PBO in the first treatment period, 200 mcg MK-8521 in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 - 74 (10 Days) (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily dose of sc MK-8521 over 10 days: 50 mcg Days 1-5, 74 mcg Days 6-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 - 150 (10 Days) (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily dose of sc MK-8521 over 10 days: 100 mcg Days 1-5, 150 mcg Days 6-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>125 - 150 (10 Days) (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily dose of sc MK-8521 over 10 days: 125 mcg Days 1-5, 150 mcg Days 6-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>72 - 125 (14 Days) (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily dose of sc MK-8521 over 14 days in older and obese participants: 72 mcg Days 1-7, 125 mcg Days 8-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO (10 Days) (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for sc MK-8521 once daily over 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO (14 Days) (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for sc MK-8521 once daily over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-PBO-Low (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc high dose MK-8521 in the first treatment period, PBO in the second period, and low dose MK-8521 in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-High-PBO (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc low dose MK-8521 in the first treatment period, high dose MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-PBO-High (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc low dose MK-8521 in the first treatment period, PBO in the second period, and high dose MK-8521 in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO-High-Low (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc PBO in the first treatment period, high dose MK-8521 in the second period, and low dose MK-8521 in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO-Low-High (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc PBO in the first treatment period, low dose MK-8521 in the second period, and high dose MK-8521 in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Low-PBO (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose sc high dose MK-8521 in the first treatment period, low dose MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>Single dose 100 mcg sc injection in a treatment period (Part 1)</description>
    <arm_group_label>100 - PBO (Part1)</arm_group_label>
    <arm_group_label>100 - 300 (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>Single dose 150 mcg sc injection in a treatment period (Part 1)</description>
    <arm_group_label>150 - PBO - 175 (Part 1)</arm_group_label>
    <arm_group_label>150 - 200 - 175 (Part 1)</arm_group_label>
    <arm_group_label>150 - 200 - PBO (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>Single dose 300 mcg sc injection in a treatment period (Part 1)</description>
    <arm_group_label>PBO - 300 (Part 1)</arm_group_label>
    <arm_group_label>100 - 300 (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>Single dose 200 mcg sc injection in a treatment period (Part 1)</description>
    <arm_group_label>150 - 200 - 175 (Part 1)</arm_group_label>
    <arm_group_label>150 - 200 - PBO (Part 1)</arm_group_label>
    <arm_group_label>PBO - 200 - 175 (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mk-8521</intervention_name>
    <description>Single dose 175 mcg sc injection in a treatment period (Part 1)</description>
    <arm_group_label>150 - PBO - 175 (Part 1)</arm_group_label>
    <arm_group_label>150 - 200 - 175 (Part 1)</arm_group_label>
    <arm_group_label>PBO - 200 - 175 (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose placebo sc injection in a treatment period (Part 1)</description>
    <arm_group_label>100 - PBO (Part1)</arm_group_label>
    <arm_group_label>PBO - 300 (Part 1)</arm_group_label>
    <arm_group_label>150 - PBO - 175 (Part 1)</arm_group_label>
    <arm_group_label>150 - 200 - PBO (Part 1)</arm_group_label>
    <arm_group_label>PBO - 200 - 175 (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>50 mcg sc injection once each day for 5 days (Part 2)</description>
    <arm_group_label>50 - 74 (10 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>74 mcg sc injection once each day for 5 days (Part 2)</description>
    <arm_group_label>50 - 74 (10 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>100 mcg sc injection once each day for 5 days (Part 2)</description>
    <arm_group_label>100 - 150 (10 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>125 mcg sc injection once each day for 5 days (Part 2)</description>
    <arm_group_label>125 - 150 (10 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>150 mcg sc injection once each day for 5 days (Part 2)</description>
    <arm_group_label>100 - 150 (10 Days) (Part 2)</arm_group_label>
    <arm_group_label>125 - 150 (10 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>72 mcg sc injection once each day for 7 days (Part 2)</description>
    <arm_group_label>72 - 125 (14 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>125 mcg sc injection once each day for 7 days (Part 2)</description>
    <arm_group_label>72 - 125 (14 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sc injection once each day for 10 days (Part 2)</description>
    <arm_group_label>PBO (10 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sc injection once each day for 14 days (Part 2)</description>
    <arm_group_label>PBO (14 Days) (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>Single low dose sc injection in a treatment period (Part 3)</description>
    <arm_group_label>High-PBO-Low (Part 3)</arm_group_label>
    <arm_group_label>Low-High-PBO (Part 3)</arm_group_label>
    <arm_group_label>Low-PBO-High (Part 3)</arm_group_label>
    <arm_group_label>PBO-High-Low (Part 3)</arm_group_label>
    <arm_group_label>PBO-Low-High (Part 3)</arm_group_label>
    <arm_group_label>High-Low-PBO (Part 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>Single high dose sc injection in a treatment period (Part 3)</description>
    <arm_group_label>High-PBO-Low (Part 3)</arm_group_label>
    <arm_group_label>Low-High-PBO (Part 3)</arm_group_label>
    <arm_group_label>Low-PBO-High (Part 3)</arm_group_label>
    <arm_group_label>PBO-High-Low (Part 3)</arm_group_label>
    <arm_group_label>PBO-Low-High (Part 3)</arm_group_label>
    <arm_group_label>High-Low-PBO (Part 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single Placebo sc injection in a treatment period (Part 3)</description>
    <arm_group_label>High-PBO-Low (Part 3)</arm_group_label>
    <arm_group_label>Low-High-PBO (Part 3)</arm_group_label>
    <arm_group_label>Low-PBO-High (Part 3)</arm_group_label>
    <arm_group_label>PBO-High-Low (Part 3)</arm_group_label>
    <arm_group_label>PBO-Low-High (Part 3)</arm_group_label>
    <arm_group_label>High-Low-PBO (Part 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males of either 18 to 45 or 45 to 70 years of age depending on the component of the
             study

          -  Body Mass Index between either 18-25 or 30-40 kg/m^2 depending on the component of the
             study

          -  Is in good health

          -  Is a non-smoker and/or has not used nicotine for at least 3 months

        Exclusion Criteria:

          -  Is mentally or legally incapacitated, has significant emotional problems or has a
             history of psychiatric disorders in the past 5 years

          -  Has a history of the following abnormalities or diseases: endocrine, gastrointestinal,
             cardiovascular, hematological, hepatic, immunological, renal, respiratory,
             genitourinary, or major neurological.

          -  History of cancer

          -  History of significant multiple or severe allergies or has had an anaphylactic
             reaction or significant intolerability to drugs or food

          -  Positive for hepatitis B surface antigen, hepatitis C antibodies or human
             immunodeficiency virus (HIV)

          -  Had major surgery, donated or lost 1 unit (500 mL) of blood or participated in another
             study within prior 4 weeks

          -  Has irritable bowel disease or recurrent nausea, vomiting, diarrhea or abdominal pain

          -  History of acute or chronic pancreatitis

          -  Uses 2 weeks prior to trial, or anticipates using during trial, medications, drugs or
             herbal remedies such as St. John's Wort

          -  Consumes greater than 3 glasses of alcohol per day

          -  Consumes greater than 6 servings of caffeinated beverages per day

          -  Regularly uses illicit drugs or has a history of drug (including alcohol) abuse within
             prior 3 months

          -  Has known hypersensitivity to glucagon or any glucagon like peptide 1 (GLP-1) receptor
             agonist

          -  Is unwilling/unable to consume standardized meals and/or is on a carbohydrate
             restricted diet

          -  Has history of hypersensitivity to pharmacologic insulins
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

